A new study identifies SPRY4 as a tumor suppressor in acute myeloid leukemia and shows that loss of SPRY4 acts as an alternative mechanism to drive RAS signaling. In addition, a paradigm of cooperativity in which combined loss of multiple negative regulators of the RAS pathway supplants the need for RAS mutations is suggested.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kim, H.J. & Bar-Sagi, D. Nat. Rev. Mol. Cell Biol. 5, 441–450 (2004).
Pratilas, C.A. et al. Proc. Natl. Acad. Sci. USA 106, 4519–4524 (2009).
Stowe, I.B. et al. Genes Dev. 26, 1421–1426 (2012).
Maertens, O. & Cichowski, K. Adv. Biol. Regul. 55, 1–14 (2014).
Shaw, A.T. et al. Genes Dev. 21, 694–707 (2007).
Zhao, Z. et al. Nat. Genet. 47, 539–543 (2015).
Feldser, D.M. et al. Nature 468, 572–575 (2010).
Junttila, M.R. et al. Nature 468, 567–571 (2010).
Xu, J. et al. Cancer Discov. 3, 993–1001 (2013).
Min, J. et al. Nat. Med. 16, 286–294 (2010).
McLaughlin, S.K. et al. Cancer Cell 24, 365–378 (2013).
De Raedt, T. et al. Nature 514, 247–251 (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Lock, R., Cichowski, K. Loss of negative regulators amplifies RAS signaling. Nat Genet 47, 426–427 (2015). https://doi.org/10.1038/ng.3299
Published:
Issue Date:
DOI: https://doi.org/10.1038/ng.3299
